CRSP vs. MNTA, NVAX, FATE, ALLO, ADVM, NBIX, TECH, QGEN, RGEN, and PCVX
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Fate Therapeutics (FATE), Allogene Therapeutics (ALLO), Adverum Biotechnologies (ADVM), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), and Vaxcyte (PCVX). These companies are all part of the "medical" sector.
Momenta Pharmaceuticals (NASDAQ:MNTA) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
CRISPR Therapeutics has a consensus price target of $73.46, suggesting a potential upside of 26.94%. Given Momenta Pharmaceuticals' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Momenta Pharmaceuticals.
In the previous week, CRISPR Therapeutics had 19 more articles in the media than Momenta Pharmaceuticals. MarketBeat recorded 19 mentions for CRISPR Therapeutics and 0 mentions for Momenta Pharmaceuticals. Momenta Pharmaceuticals' average media sentiment score of 0.90 beat CRISPR Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.
CRISPR Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -757.61%. Momenta Pharmaceuticals' return on equity of -11.56% beat CRISPR Therapeutics' return on equity.
CRISPR Therapeutics has higher revenue and earnings than Momenta Pharmaceuticals. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Momenta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Momenta Pharmaceuticals received 108 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 66.59% of users gave Momenta Pharmaceuticals an outperform vote while only 65.43% of users gave CRISPR Therapeutics an outperform vote.
Momenta Pharmaceuticals has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Summary
CRISPR Therapeutics beats Momenta Pharmaceuticals on 14 of the 17 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
